Form 4: Rocket Pharmaceuticals CFO Aaron Ondrey Reports Stock and Option Transactions

Chief Financial Officer Aaron Ondrey of Rocket Pharmaceuticals reports acquisition of restricted stock units (RSUs) and stock options, along with the disposal of common stock.

Summary

• On February 11, 2025, Aaron Ondrey, the Chief Financial Officer of Rocket Pharmaceuticals, engaged in transactions involving the company's stock.
• Ondrey acquired 90,358 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs convert to common stock on a one-for-one basis and vest over three years, starting February 11, 2026, with one-third vesting initially and the remainder in equal quarterly installments.
• Additionally, Ondrey acquired options to purchase 134,642 shares of common stock at an exercise price of $9.88.
• These options also vest over three years, beginning February 11, 2026, with one-third vesting initially and the remainder in equal quarterly installments, contingent upon continued employment.
• Ondrey also disposed of 137,139 shares of common stock.
• Following these transactions, Ondrey beneficially owns 137,139 shares of common stock and 134,642 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The disposal of shares is slightly negative, but the acquisition of RSUs and options is slightly positive. Overall, it doesn't strongly indicate a positive or negative outlook.

Positives

• The granting of RSUs and stock options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued employment and commitment from the CFO.

Negatives

• The disposal of 137,139 shares by the CFO could be perceived negatively by investors, although the reason for the disposal is not specified.

Risks

• The vesting of the RSUs and stock options is contingent upon the CFO's continued employment, creating a potential risk if he were to leave the company.
• The disposal of shares by an insider could signal a lack of confidence in the company's future prospects, although this is not necessarily the case.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry, used to attract and retain key personnel.
• Vesting schedules of three years with quarterly installments are also typical in the industry, aligning with long-term value creation.
• Comparable companies like Bluebird Bio and CRISPR Therapeutics also utilize similar equity compensation structures.

Stakeholder Impact

• Shareholders may be interested in the CFO's transactions as an indicator of his confidence in the company.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates